Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Olema Pharmaceuticals, Inc.
Market Cap
$697.52M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$698.13M
EBITDA Margin
-4821.38%
TTM Avg
-3832.53%
3Y Avg
-2582.73%
5Y Avg
-1806.92%
Market Cap
$702.28M
EBITDA Margin
-123018.64%
TTM Avg
-69257.96%
3Y Avg
-35033.94%
5Y Avg
-23599.85%
Market Cap
$712.63M
EBITDA Margin
52.93%
TTM Avg
53.31%
3Y Avg
49.89%
5Y Avg
44.80%
Market Cap
$682.26M
EBITDA Margin
-1285.45%
TTM Avg
-897.10%
3Y Avg
-897.10%
5Y Avg
-897.10%
Market Cap
$679.70M
EBITDA Margin
-547.98%
TTM Avg
-848.64%
3Y Avg
-1500.78%
5Y Avg
-1508.87%
Market Cap
$721.26M
EBITDA Margin
-14.10%
TTM Avg
-9.55%
3Y Avg
-6.60%
5Y Avg
-0.48%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | $697.52M | N/A | N/A | N/A | N/A |
| Anteris Technologies Global Corp. (AVR)vs › | $698.13M | -4821.38% | -3832.53% | -2582.73% | -1806.92% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $702.28M | -123018.64% | -69257.96% | -35033.94% | -23599.85% |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $712.63M | 52.93% | 53.31% | 49.89% | 44.80% |
| Solid Biosciences Inc. (SLDB)vs › | $682.26M | -1285.45% | -897.10% | -897.10% | -897.10% |
| Verastem, Inc. (VSTM)vs › | $679.70M | -547.98% | -848.64% | -1500.78% | -1508.87% |
| Faeth Therapeutics, Inc. (FTH)vs › | $718.03M | N/A | N/A | N/A | N/A |
| Cytek Biosciences, Inc. (CTKB)vs › | $721.26M | -14.10% | -9.55% | -6.60% | -0.48% |
| ArriVent BioPharma, Inc. (AVBP)vs › | $672.77M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $668.98M | 18.82% | 18.71% | 11.51% | 4.96% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
